Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication

Antiviral Therapy

Volumn 13, Issue 1, 2008, Pages 57-66

  Lutgehetmann, Marc ^a   Volz, Tassilo ^a   Quaas, Alexander ^a   Zankel, Myrga ^b   Fischer, Conrad ^c   Dandri, Maura ^a   Petersen, Joerg ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b Essex Pharma   (Germany)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; CIRCULAR DNA; HEPATITIS E ANTIGEN; PEGINTERFERON ALPHA2B; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; MALE; MONOTHERAPY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; SEROLOGY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INTERFERON ALFA-2B; LIVER; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; VIRUS REPLICATION;

EID: 42149135950     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol 2007; 13:48-64.
2. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71:9392-9399.
3. Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001; 33:981-988.
4. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104-1108.
5. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128:1890-1897.
6. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758.
7. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006; 11:909-916.
8. Tsiang M, Gibbs CS. Analysis of hepatitis B virus dynamics and its impact on antiviral development. Methods Mol Med 2004; 96:361-377.
9. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29:1863-1869.
10. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722.
11. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alpha-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
12. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365:123-129.
13. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alpha-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
14. Colombatto P, Civitano L, Bizzarri R, et al. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-α2a, lamivudine and combination therapy. Antivir Ther 2006; 11:197-212.
15. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56:699-705.
16. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44:675-684.
17. Gerlich WH, Wend U, Glebe D. Quantitative assay of hepatitis B surface antigen in serum or plasma using laurell electrophoresis. Methods Mol Med 2004; 95:57-63.
18. Loeb KR, Jerome KR, Goddard J, Huang M, Cent A, Corey L. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 2000; 32:626-629.
19. Desmet VI, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751.
21. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
22. Jang MK, Chung YH, Choi MH, et al. Combination of alpna-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol 2004; 19:1363-1368.
23. Yuen MF, Lai CL. Combination therapy for chronic hepatitis B: simultaneous or sequential? Am J Gastroenterol 2007; 102:105-106.
24. Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133:843-852.
25. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44:422-431.